Cereno Scientific AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
5
Active:1
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Cereno Scientific AB
- Registration Number
- NCT06321705
- Locations
- 🇸🇪
Fredrik Frick, Gothenburg, Sweden
Effect of CS1 in Subjects With Pulmonary Arterial Hypertension
Phase 2
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: CS1 Administration
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Cereno Scientific AB
- Target Recruit Count
- 25
- Registration Number
- NCT05224531
- Locations
- 🇸🇪
Fredrik Frick, Gothenburg, Sweden
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Cereno Scientific AB
- Target Recruit Count
- 30
- Registration Number
- NCT03903302
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
News
No news found